论文部分内容阅读
作者回顾性分析48例老年(≥65岁)及70例年轻(≤64岁)小细胞肺癌(SCLC)患者。全部病例均经组织学证实为 SCLC,并分为局限期病变(癌病限于一个肺和同侧淋巴结)和广泛期病变。34例老年和62例年轻患者进行联合化疗。联合化疗方案有 VAC(环磷酰胺、阿霉素、长春新碱),ACE(环磷酰胺、阿霉素、鬼臼乙叉甙),COMP(罗氮芥、长春新碱、甲氨蝶呤、甲基苄肼)。结果老年组和年轻组的病变程度和性别比率均无统计学差异。联合化疗组中位生存期25周,远超过单一药物治疗组(10周),拒绝治疗患者生存期8周,危重未能治疗患者生存期3周,
The authors retrospectively analyzed 48 elderly (≥65 years) and 70 young (≤64 years) small cell lung cancer (SCLC) patients. All cases were histologically confirmed as SCLC and were divided into localized lesions (cancer limited to one lung and ipsilateral lymph nodes) and extensive disease. 34 elderly and 62 young patients underwent combined chemotherapy. Combination chemotherapy regimens include VAC (cyclophosphamide, doxorubicin, vincristine), ACE (cyclophosphamide, doxorubicin, etoposide), COMP (rutin, vincristine, methotrexate , Procarbazine). Results There was no significant difference in the degree of disease and sex between the elderly group and the young group. The combined chemotherapy group median survival of 25 weeks, far more than a single drug treatment group (10 weeks), refused to treat patients with survival of 8 weeks, critically ill patients failed to treat the survival of 3 weeks,